Transgenic models to study the actions of cytokines in the central nervous system

NeuroImmunoModulation

Volumn 5, Issue 3-4, 1998, Pages 126-135

  Campbell, Iain L ^a   Stalder, Anna K ^a,c   Akwa, Yvette ^a,b   Pagenstecher, Axel ^a,d   Asensio, Valérie C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Fondation pour la Rech Med   (France)

^c National Multiple Sclerosis Society   (United States)

^d Deutsche Forschungsgemeinschaft   (Germany)

Author keywords

Central nervous system; Cytokine; Neurological disorders; Transgenic mice

Indexed keywords

ALPHA INTERFERON; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 12; INTERLEUKIN 3; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ASTROCYTE; CENTRAL NERVOUS SYSTEM; GENE EXPRESSION; GENE TARGETING; IMMUNOMODULATION; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC;

EID: 0031713845     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026329     Document Type: Review

References (58)

1. Plata-Salaman CR: Immunoregulators in the nervous system. Biobehav Rev 1991;15:185-215.
2. Merrill JE, Benveniste EN: Cytokines in inflammatory brain lesions: Helpful and harmful. Trends Neurosci 1996;19:331-338.
3. Sternberg EM: Emotions and disease: From balance of humors to balance of molecules. Nat Med 1997;3:264-267.
4. Campbell IL: Neuropathogenic actions of cytokines assessed in transgenic mice. Int J Dev Neurosci 1995;13:275-284.
5. Campbell IL, Stalder AK, Chiang C-S, Bellinger R, Heyser CJ, Steffensen S, Masliah E, Powell HC, Gold LH, Henriksen SJ, Siggins GR: Transgenic models to assess the neuropathogenic actions of cytokines in the central nervous system. Mol Psychiatry 1997;2:125-129.
6. Benveniste EN: Inflammatory cytokines within the central nervous system: Sources, function, and mechanism of action. Am J Physiol 1992; 263:C1-C16.
7. Campbell IL, Powell HC: Role of cytokines in demyelinating disease studied in transgenic mice. Methods 1996;10:462-477.
8. Campbell IL, Gold LH: Transgenic modeling of neuropsychiatrie disorders. Mol Psychiatry 1996;1:105-120.
9. Chiang C-S, Powell HC, Gold L, Samimi A, Campbell IL: Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J Clin Invest 1996;97:1512-1524.
10. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MBA, Mucke L: Neurologic disease induced in transgenic mice by the cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 1993;90:10061-10065.
11. Pagenstecher A, Stalder AK, Campbell IL: Transgenic expression of IL-12 in astrocytes leads to diffuse lymphocytic encephalomyelitis. Soc Neurosci Abstr 1997;23:993.
12. Akwa Y, Eloranta ML, Sandberg K, Powell HC, Bloom FE, Campbell IL: Encephalopathy induced by the astrocyte-targeted expression of interferon-a in transgenic mice. Soc Neurosci Abstr 1996;22:278.
13. Stalder AK, Pagenstecher A, Campbell IL: Lymphocytic meningoencephalomyelitis induced by the transgenic expression of TNF-α in the CNS. Soc Neurosci Abstr 1996;22:1455.
14. Frendl G, Beller DI: Regulation of macrophage activation by IL-3. J Immunol 1990;144:3392-3399.
15. Lee TT, Martin FC, Merrill JE: Lymphokine induction of rat microglia multinucleated giant cell formation. Glia 1993;8:51-61.
16. Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH: Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin-6 in the brain. Proc Natl Acad Sci USA 1997;94:1500-1505.
17. Chiang C-S, Stalder A, Samimi A, Campbell IL: Reactive gliosis as a consequence of interleukin-6 expression in the brain. Studies in transgenic mice. Dev Neurosci 1994;16:212-221.
18. Campbell IL: Proliferative angiopathy in the brain induced by the cerebral overexpression of interleukin-6 in transgenic mice. J Cell Biochem 1994;18A:283.
19. Brett FM, Mizisin AP, Powell HC, Campbell IL: Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol 1995;54: 766-775.
20. Barnum SR, Jones JL, Muller-Ladner U, Samimi A, Campbell IL: Chronic complement C3 gene expression in the CNS of transgenic mice with astrocyte-targeted interleukin-6 expression. Glia 1996;18:107-117.
21. Hernandez J, Molinero A, Campbell IL, Hildago J: Transgenic expression of interleukin-6 in the central nervous system regulates brain metallothionein-I and -III expression in mice. Brain Res 1997;48:125-131.
22. Steffensen SC, Campbell IL, Henriksen SJ: Site-specific hippocampal pathophysiology due to cerebral overexpression of interleukin-6 in transgenic mice. Brain Res 1994;652:149-153.
23. Bellinger FP, Madamba SG, Campbell IL, Siggins G: Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci Lett 1995;198:95-98.
24. Raber J, O'Shea RD, Bloom FE, Campbell IL: Modulation of hypothalamic-pituitary-adrenal function by transgenic expression of interleukin-6 in the CNS of mice. J Neurosci 1997; 17: 9473-9480.
25. Trinchieri G: Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-276.
26. Stalder A, Pagenstecher A, Yu NC, Kincaid C, Chiang C-S, Hobbs MV, Bloom FE, Campbell IL: Lipopolysaccharide induced interleukin-12 expression in the CNS and cultured astrocytes and microglia. J Immunol 1997;159:1344-1351.
27. Becher B, Dodelet V, Fedorowicz V, Antel JP: Soluble tumor necrosis factor receptor inhibits interleukin 12 production by stimulated human adult microglial cells in vitro. J Clin Invest 1996;98:1539-1543.
28. Park J-H, Shin S-H: Induction of IL-12 gene expression in the brain in septic shock. Biochem Biophys Res Commun 1996;224:391-396.
29. Aloisi F, Penna G, Cerase J, Iglesias B, Adorini L: IL-12 production by central nervous system microglia is inhibited by astrocytes. J Immunol 1997;159:1604-1612.
30. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL: Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 1997;94:599-603.
31. Leonard JP, Waldburger KE, Goldman SJ: Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995;181:381-386.
32. Smith T, Hewson AK, Kingsley CI, Leonard JP, Cuzner ML: Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol 1997; 150:1909-1917.
33. Waldburger KE, Hastings RC, Schaub RG, Goldman SJ, Leonard JP: Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Am J Pathol 1996;2:375-382.
34. Bocci V: Central nervous system toxicity of interferons and other cytokines. J Biol Regul Homeost Agents 1988;2:107-118.
35. Gutterman JU: Cytokine therapeutics: Lessons from interferon α. Proc Natl Acad Sci USA 1994;91:1198-1205.
36. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA: The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15.
37. Sandberg K, Kemper P, Stalder A, Zhang J, Hobbs MV, Whitton JL, Campbell IL: Altered tissue distribution of viral replication and T-cell spreading is pivotal in the protection against fatal lymphocytic choriomeningitis in mice after neutralization of IFN-α/β. J Immunol 1994;153:220-231.
38. Sandberg K, Eloranta M-L, Campbell IL: Expression of alpha/beta interferons (IFN-α/β) and their relationship to IFN-α/β-induced genes in lymphocytic choriomeningitis. J Virol 1994;68:7358-7366.
39. Beutler B, Grau GE: Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med 1993;21:S423-S435.
40. Feuerstein GZ, Liu T, Barone FC: Cytokines, inflammation, and brain injury: Role of tumor necrosis factor-α. Cerebrovasc Brain Metab Rev 1994;6:341-360.
41. Fiers W: Tumor necrosis factor: Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991;285:199-212.
42. Akassoglou K, Probert L, Kontogeorgos G, Kollias G: Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 1997; 158:438-445.
43. Louis J-C, Magal E, Takayama S, Varon S: CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science 1993;259:689-692.
44. Andersson P-B, Perry VH, Gordon S: The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues. Neuroscience 1992;48: 169-186.
45. Butcher EC: Cellular and molecular mechanisms that direct leukocyte traffic. Am J Pathol 1990;136:3-11.
46. Steffen BJ, Breier G, Butcher EC, Schulz M, Engelhardt B: ICAM-1, VCAM-1, and MAd-CAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro. Am J Pathol 1996;148: 1819-1838.
47. Haelens A, Wuyts A, Proost P, Struye S, Opdenakker G, van Damme J: Leukocyte migration and activation by murine chemokines. Immunobiology 1996;195:499-521.
48. Schall TJ, Bacon KB: Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994;6:865-873.
49. Taub DD: Chemokine-leukocyte interactions - the voodoo that they do so well. Cytokine Growth Factor Rev 1996;7:355-376.
50. Ransohoff RM, Glabinski A, Tani M: Chemokines in immune-mediated inflammation of the central nervous system. Cytokine Growth Factor Rev 1996;7:35-46.
51. Tani M, Ransohoff M: Do chemokines mediate inflammatory cell invasion of the central nervous system parenchyma? Brain Pathol 1994; 4:135-143.
52. Asensio VC, Pagenstecher A, Campbell IL: Prominent expression of chemokine ClO in experimental inflammatory demyelinating diseases of the CNS. Soc Neurosci Abstr 1997;23: 992.
53. Goetzl EJ, Banda MJ, Leppert D: Matrix metalloproteinases in immunity. J Immunol 1996; 156:1-4.
54. Gijbels K, Masure S, Carton H, Opdenakker G: Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992; 41:29-34.
55. Gijbels K, Galardy RE, Steinman L: Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994;94:2177-2182.
56. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G: Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993;36: 432-440.
57. Clements JM, Cossins JA, Wells GMA, Corkill DJ, Helfrich K, Wood LM, Pigott R, Stabler G, Ward GA, Gearing AJH, Miller KM: Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-α inhibitor. J Neuroimmunol 1997;74:85-94.
58. Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL: Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse CNS in normal and inflammatory states. Am J Pathol 1998;152:729-741.